256: Explaining the E.U.'s pharma overhaul, Lilly's booming business, & a long-awaited drug approval
The Readout Loud
00:00
Eli Lilly's Mount Gero Sales for the Quarter Come in at $568.5 Million
Mount Gero sales for the quarter came in at $568.5 million, including U.S. sales of $536 million. That is a huge beat above consensus for what people were expecting this quarter. As you mentioned, they are also obviously seeking to expand use of that drug into obesity. And then beyond that, any day now, I guess, technically, will we learn the results of a phase three trial of Eli Lilly's treatment for Alzheimer's disease, Denanemab.
Transcript
Play full episode
